Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Mihelich, Brittany L ^a   Maranville, Joseph C ^b   Nolley, Rosalie ^c   Peehl, Donna M ^c   Nonn, Larisa ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LET 7A; MICRORNA; MICRORNA 100; MICRORNA 103; MICRORNA 106A; MICRORNA 107; MICRORNA 1207 5P; MICRORNA 125B; MICRORNA 130B; MICRORNA 141; MICRORNA 146A; MICRORNA 182; MICRORNA 183; MICRORNA 223; MICRORNA 24; MICRORNA 26B; MICRORNA 30C; MICRORNA 451; MICRORNA 874; MICRORNA 93; MICRORNA 96; MIR 1274A; UNCLASSIFIED DRUG; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOCHEMICAL RECURRENCE; BLOOD LEVEL; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA ANALYSIS; BLOOD; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; ODDS RATIO; PATHOLOGY; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; LOGISTIC MODELS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 84928882481     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124245     Document Type: Article

References (39)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29. doi: 10.3322/caac.21208 PubMed PMID: 24399786.
2. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA: the journal of the American Medical Association. 2014; 311(11):1143-9. doi: 10.1001/jama.2014.2085 PubMed PMID: 24643604.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0 PubMed PMID: 25108889.
4. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(2):228-34. doi: 10.1200/JCO.2010.31.4252 PubMed PMID: 21115873; PubMed Central PMCID: PMC3058278.
5. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(1):126-31. doi: 10.1200/JCO.2009.24.2180 PubMed PMID: 19917860.
6. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. European urology. 2012; 61(5):1019-24. doi: 10.1016/j.eururo.2012.01.050 PubMed PMID: 22336380.
7. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA: the journal of the American Medical Association. 1999; 281(15):1395-400. PubMed PMID: 10217055.
8. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. The Journal of urology. 2005; 173(6):1938-42. doi: 10.1097/01.ju.0000158155.33890.e7 PubMed PMID: 15879786; PubMed Central PMCID: PMC2948569.
9. Thompson IM Jr., Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, et al. Long-term survival of participants in the prostate cancer prevention trial. The New England journal of medicine. 2013; 369(7):603-10. doi: 10.1056/NEJMoa1215932 PubMed PMID: 23944298.
10. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer research. 2011; 71(2):550-60. doi: 10.1158/0008-5472.CAN-10-1229 PubMed PMID: 21098088; PubMed Central PMCID: PMC3022112.
11. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. British journal of cancer. 2012; 106(4):768-74. doi: 10.1038/bjc.2011.595 PubMed PMID: 22240788; PubMed Central PMCID: PMC3322952.
12. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001; 294(5543):858-62. doi: 10.1126/science.1065062 PubMed PMID: 11679671.
13. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. International journal of cancer Journal international du cancer. 2011; 128(3):608-16. doi: 10.1002/ijc.25376 PubMed PMID: 20473869.
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(30):10513-8. doi: 10.1073/pnas.0804549105 PubMed PMID: 18663219; PubMed Central PMCID: PMC2492472.
15. Sapre N, Selth LA. Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. Prostate cancer. 2013; 2013:539680. doi: 10.1155/2013/539680 PubMed PMID: 23577261; PubMed Central PMCID: PMC3610368.
16. Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, et al. Combinations of Serum Prostate-Specific Antigen and Plasma Expression Levels of let-7c, miR-30c, miR-141, and miR-375 as Potential Better Diagnostic Biomarkers for Prostate Cancer. DNA and cell biology. 2014. doi: 10.1089/dna.2014.2663 PubMed PMID: 25521481.
17. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, et al. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PloS one. 2014; 9(6):e98597. doi: 10.1371/journal.pone.0098597 PubMed PMID: 24893170; PubMed Central PMCID: PMC4043973.
18. Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, et al. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget. 2014; 5(3):824-40. PubMed PMID: 24583788; PubMed Central PMCID: PMC3996656.
19. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British journal of cancer. 2013; 109(3):641-50. doi: 10.1038/bjc.2013.369 PubMed PMID: 23846169; PubMed Central PMCID: PMC3738112.
20. Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. The Prostate. 2013; 73(4):346-54. doi: 10.1002/pros.22572 PubMed PMID: 22887127; PubMed Central PMCID: PMC3980954.
21. Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, et al. Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. Anticancer research. 2014; 34(2):665-9. PubMed PMID: 24510997.
22. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. The Prostate. 2012; 72(13):1469-77. doi: 10.1002/pros.22499 PubMed PMID: 22298119; PubMed Central PMCID: PMC3368098.
23. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008; 3(6):1101-8. PubMed PMID: 18546601.
24. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC bioinformatics. 2011; 12:77. doi: 10.1186/1471-2105-12-77 PubMed PMID: 21414208; PubMed Central PMCID: PMC3068975.
25. Giangreco AA, Vaishnav A, Wagner D, Finelli A, Fleshner N, Van der Kwast T, et al. Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer prevention research. 2013; 6(5):483-94. doi: 10.1158/1940-6207.CAPR-12-0253 PubMed PMID: 23503652; PubMed Central PMCID: PMC3644314.
26. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, Giangreco AA, et al. miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. The Journal of biological chemistry. 2011; 286(52):44503-11. doi: 10.1074/jbc.M111.262915 PubMed PMID: 22045813; PubMed Central PMCID: PMC3247959.
27. Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ, et al. Elevated levels of circulating micro-RNA-200 family members correlate with serous epithelial ovarian cancer. BMC cancer. 2012; 12:627. doi: 10.1186/1471-2407-12-627 PubMed PMID: 23272653; PubMed Central PMCID: PMC3542279.
28. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of surgery. 2010; 251(3):499-505. doi: 10.1097/SLA.0b013e3181cc939f PubMed PMID: 20134314.
29. Schopman NC, Heynen S, Haasnoot J, Berkhout B. A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA biology. 2010; 7(5):573-6. doi: 10.4161/rna.7.4.13141 PubMed PMID: 20818168.
30. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis. 1997; 18(6):1225-31. PubMed PMID: 9214606.
31. Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B. Circulating miRNAs: cell-cell communication function? Frontiers in genetics. 2013; 4:119. doi: 10.3389/fgene.2013.00119 PubMed PMID: 23825476; PubMed Central PMCID: PMC3695387.
32. Chen Q, Zhao X, Zhang H, Yuan H, Zhu M, Sun Q, et al. MiR-130b suppresses prostate cancer metastasis through down-regulation of MMP2. Molecular carcinogenesis. 2014. doi: 10.1002/mc.22204 PubMed PMID: 25154741.
33. Dong Q, Meng P, Wang T, Qin W, Qin W, Wang F, et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PloS one. 2010; 5(4):e10147. doi: 10.1371/journal.pone.0010147 PubMed PMID: 20418948; PubMed Central PMCID: PMC2854685.
34. Goto Y, Kojima S, Nishikawa R, Enokida H, Chiyomaru T, Kinoshita T, et al. The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget. 2014; 5(17):7748-59. PubMed PMID: 25115396; PubMed Central PMCID: PMC4202158.
35. McCann MJ, Rowland IR, Roy NC. The anti-proliferative effects of enterolactone in prostate cancer cells: evidence for the role of DNA Licencing genes, mi-R106b cluster expression, and PTEN dosage. Nutrients. 2014; 6(11):4839-55. doi: 10.3390/nu6114839 PubMed PMID: 25372501; PubMed Central PMCID: PMC4245566.
36. Sun Q, Zhao X, Liu X, Wang Y, Huang J, Jiang B, et al. miR-146a functions as a tumor suppressor in prostate cancer by targeting Rac1. The Prostate. 2014; 74(16):1613-21. doi: 10.1002/pros.22878 PubMed PMID: 25214035.
37. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. Journal of translational medicine. 2012; 10:55. doi: 10.1186/1479-5876-10-55 PubMed PMID: 22440013; PubMed Central PMCID: PMC3340316.
38. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer prevention research. 2012; 5(3):492-7. doi: 10.1158/1940-6207.CAPR-11-0370 PubMed PMID: 22158052.
39. Sanders I, Holdenrieder S, Walgenbach-Brunagel G, von Ruecker A, Kristiansen G, Muller SC, et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. International journal of urology: official journal of the Japanese Urological Association. 2012; 19(11):1017-25. doi: 10.1111/j.1442-2042.2012.03082.x PubMed PMID: 22788411.